InsiderTrades

Form 4 for MGNX MACROGENICS INC

Accepted 2024-03-06 00:00:00 ET · period of report 2024-03-04 · accession 0001125345-24-000056 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-03-06 2024-03-04 MGNX Risser Eric Blasius COO M - OptEx $10.15 +15.0K 80.1K +23% +$152.2K
DM 2024-03-06 2024-03-04 MGNX Risser Eric Blasius COO S - Sale+OE $19.76 -41.2K 38.9K -51% -$813.5K
D 2024-03-06 2024-03-04 MGNX Risser Eric Blasius COO M - OptEx $0.00 -15.0K 155.0K -9% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-03-04 M A 15,000 $10.15 80,059 D — —
2 Common Common Stock 2024-03-04 S D 15,000 $20.00 65,059 D — —
3 Common Common Stock 2024-03-04 S D 26,159 $19.63 38,900 D — — (F2) This transaction was executed in multiple trades at prices ranging from $19.50 to $19.78. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4 Derivative Employee stock option (right to buy) 2024-03-04 M D 15,000 $0.00 155,000 D $10.15 · — to 2032-02-22 15,000 Common Stock (F3) 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.